To Get Full Access :
Voyxact® (sibeprenlimab-szsi) is an FDA-approved prescription medicine used to reduce proteinuria (protein in the urine) in adults with primary IgA nephropathy (IgAN) who are at risk of disease progression. This approval is under the FDA’s accelerated approval pathway, based on the reduction of proteinuria. Its long-term impact on slowing kidney function decline is still being studied in confirmatory trials.
Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets
For full access Sign-up / Sign-in using below Methods:
By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.
